Small caps round-up: Syntopix, Atlantic Coal, Brady...
Drug developer Syntopix shares rallied as it reported positive phase 2 results for its lead dermatological compound SYN0126, for the treatment of acneic skin. Following the results, Syntopix has decided to focus its development efforts around three specific core compounds: SYN0126, SYN1113 and SYN
Read more